Since C1INH naturally occurs in the blood of healthy patients, pdC1INH has a favorable safety profile in comparison to alternative treatments such as the androgens, which have been associated with more serious adverse events across HAE populations [2]. This evidence concerns the gene SERPING1 and hereditary angioedema.